Absci (ABSI) Gains from Investment Securities (2022)
Absci (ABSI) reported Gains from Investment Securities of $750000.0 for Q1 2022.
Absci (ABSI) Gains from Investment Securities (2022) Analysis & Trends
Absci (ABSI) has 1 years of Gains from Investment Securities data on file, last reported at $750000.0 in Q1 2022.
- For the quarter ending Q1 2022, Gains from Investment Securities changed N/A year-over-year to $750000.0; the trailing twelve-month figure through Mar 2023 stood at $750000.0 (changed 0.0% YoY), and the FY2025 full-year result was -$5.1 million, changed N/A from the prior year.
- Gains from Investment Securities steadied at $750000.0 in Q1 2022.
- In the past five years, Gains from Investment Securities ranged from a high of $750000.0 in Q1 2022 to a low of $750000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Absci | 1.17 Bn | 1.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 750,000.00 |
| Mar 31, 2022 | 750,000.00 |